NDAORALFILM
Approved
Jul 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZUPLENZ (ondansetron) by Novartis is serotonin 3 receptor antagonists [moa]. Approved for postoperative nausea and vomiting, chemotherapy-induced nausea and vomiting, nausea and vomiting. First approved in 2010.
Drug data last refreshed 21h ago
Mechanism of Action
Serotonin 3 Receptor Antagonists
Worked on ZUPLENZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.